Literature DB >> 2014493

Effect of terbutaline on bronchoconstriction induced by nebulised pentamidine.

T R Leigh1, J Wiggins, B G Gazzard, J V Collins.   

Abstract

The severity, duration, and reversibility of pentamidine induced bronchial narrowing was studied with and without pretreatment with nebulised terbutaline 10 mg in an open study of 40 patients seropositive for the human immunodeficiency virus (HIV). All subjects received pentamidine 300 mg in 5 ml water via an Acorn System 22 jet nebuliser. The forced expiratory volume in one second (FEV1) fell in all 20 patients given pentamidine alone, the mean maximum fall being 20.6%. In the 20 patients given pentamidine preceded by nebulised terbutaline the mean maximum fall in FEV1 was 4%; three subjects had a fall in FEV1 of more than 10%.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014493      PMCID: PMC462972          DOI: 10.1136/thx.46.2.122

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  5 in total

Review 1.  Pneumocystis carinii pneumonia.

Authors:  S Thomas; M O'Doherty; N Bateman
Journal:  BMJ       Date:  1990-01-27

2.  Differences in relative efficiency of nebulisers for pentamidine administration.

Authors:  M J O'Doherty; S Thomas; C Page; D Barlow; C Bradbeer; T O Nunan; N T Bateman
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

3.  Adverse reactions to the non-drug constituents of nebuliser solutions.

Authors:  R Beasley; P Rafferty; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

4.  Reversible bronchoconstriction with nebulised pentamidine.

Authors:  D E Smith; D Herd; B G Gazzard
Journal:  Lancet       Date:  1988-10-15       Impact factor: 79.321

5.  Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; E N Brunette; E T Lin; P C Hopewell
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.